Fluid Imaging Technologies and the University of Colorado have entered into an exclusive patent licensing agreement aiming for the automated detection and identification of waterborne and bloodborne bacteria.
Under the terms of the agreement, Fluid Imaging Technologies will commercialize the University's patented artificial intelligence software as the exclusive, worldwide licensee for applications involving the detection and monitoring of bacteria for diagnosis of infections in blood and other bodily fluids. The FlowCam Nano paired with the artificial intelligence software will provide a rapid means to automatically identify bacteria.
The goal will be to reduce the time required for physicians to correctly identify bacterial species causing a sepsis infection from several days to 60 minutes or less, enabling the proper antibiotic to be administered sooner than currently possible.
Read the full story online at Thomasnet